Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Still a Buy?

Key Points

• Shares of Zealand Pharma A/S gapped up to $71.98 from a previous close of $69.50, with current trading at $71.49 on a volume of 366 shares.
• The company's consensus rating is a "Buy", with five analysts rating it as a strong buy and one issuing a sell rating after recent rating changes.
• Zealand Pharma reported $16.06 EPS for the last quarter, missing estimates, with a revenue of $1.43 billion, significantly below analyst expectations of $9.18 billion.

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $69.50, but opened at $71.98. Zealand Pharma A/S shares last traded at $71.49, with a volume of 366 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Zacks Research cut Zealand Pharma A/S from a "hold" rating to a "strong sell" rating in a research report on Friday, August 15th. BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. Wells Fargo & Company raised Zealand Pharma A/S to a "strong-buy" rating in a report on Thursday, July 24th. Finally, Barclays raised Zealand Pharma A/S to a "strong-buy" rating in a report on Monday, July 7th. Five research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zealand Pharma A/S currently has a consensus rating of "Buy".

Zealand Pharma A/S Stock Performance

The stock has a market cap of $5.08 billion, a price-to-earnings ratio of 5.02 and a beta of 0.71. The stock's 50 day moving average is $58.02 and its two-hundred day moving average is $67.92. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported $16.06 EPS for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 82.30%. The firm had revenue of $1.43 billion during the quarter, compared to analyst estimates of $9.18 billion. Analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.